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Background: Extreme left ventricular hypertrophy (LVH), defined on echo as a maximum LV wall thickness of ≥30 mm is regarded as a risk factor 
for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM). Cardiovascular magnetic resonance (CMR) is increasingly being used to 
evaluate HCM and allows wall thickness to be more precisely assessed than echo. This threshold may therefore not be appropriate for CMR-derived 
data. We assessed the prognostic value of LV wall thickness as determined by CMR.
methods: Consecutive patients ≥18 yrs of age with HCM (n=711, median age: 56.3 yrs) underwent CMR and were followed for a median of 3.5 
yrs or a total of 2852 patient-years. The primary endpoint was SCD or aborted SCD (resuscitation from or appropriate implantable cardioverter 
defibrillator discharge for ventricular tachycardia/fibrillation). The secondary endpoints were cardiovascular mortality (heart failure death, SCD 
death, stroke) and aborted SCD, as well as all-cause mortality. LV wall thickness was measured from a contiguous short-axis stack of cine images at 
end-diastole. Event-free survival was analysed using the Cox proportional hazards model.
results: The mean (±SD) maximum wall thickness was 19.4±5.1 mm and 32 patients had a wall thickness ≥30 mm. At the end of follow-up, 22 
patients (3.1%) reached the primary endpoint: 2 (9.1%) with extreme LVH and 30 (4.4%) without (p=0.292). When examined in relation to both 
primary and secondary study outcomes, neither the maximum end-diastolic LV wall thickness as a continuous variable nor a cut-off value of ≥30 mm 
were significant predictors of SCD risk (Hazard Ratio [HR] for wall thickness ≥30 mm: 1.62, 95% Confidence Interval [CI]: 0.38 to 6.98, p=0.516); 
cardiovascular mortality and aborted SCD (HR: 1.68, 95% CI: 0.58 to 4.86, p=0.335); or all-cause mortality (HR: 1.39, 95% CI: 0.54 to 3.55, 
p=0.491).
conclusions: The status of extreme LVH as a cardinal risk factor for SCD or other adverse outcomes in HCM should be re-appraised. We speculate 
that the rate at which LVH develops rather than the final extent of hypertrophy may better predict SCD risk. This may account for the discrepancy 
between our findings and previous work which has studied younger cohorts.
